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Molecular targetingFocal adhesion kinase (FAK) plays a vital role in tumor cell proliferation, survival andmigration. Alteredmetabol-
ic pathways fuel rapid tumor growth by accelerating glucose, lipid and glutamine processing. Besides the mito-
genic effects of FAK, evidence is accumulating supporting the association between hyper-activated FAK and
aberrant metabolism in tumorigenesis. FAK can promote glucose consumption, lipogenesis, and glutamine de-
pendency to promote cancer cell proliferation, motility, and survival. Clinical studies demonstrate that FAK-
related alterations of tumor metabolism are associated with increased risk of developing solid tumors. Since
FAK contributes to the malignant phenotype, small molecule inhibition of FAK-stimulated bioenergetic and bio-
synthetic processes can provide a novel approach for therapeutic intervention in tumor growth and invasion.
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Cell attachment to the extracellular matrix (ECM) is involved in
fundamental activities from embryogenesis to tumorigenesis. Actin ﬁla-
ments are fastened to focal adhesions with the help of a multi-protein
complex that “adheres” actin microﬁbers to the ECM proteins. Numer-
ous proteins located in the focal adhesions or actin ﬁlament termini-
ECM joint regions have been identiﬁed such as α-actinin, ﬁlamin,
vinculin, ﬁbronectin, integrin, talin, paxillin, and focal adhesion kinase
(FAK). Focal adhesions are dynamic structures that constantly change
or reorganize in response to microenvironmental cues such as ECM al-
terations, growth factors, and nutrient availability (Fletcher & Mullins,y acid synthase; IGF1R, insulin-
, extracellularmatrix; IRS, insu-
-2-(5-phenylacetamido-1,3,4-
LUT, glucose transporter.
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ghts reserved.2010). For example, integrin engagement or growth factor stimulation
promotes FAK interactionwith Src, leading to activation of downstream
pathways such as Ras/MAPK signaling (Guan & Shalloway, 1992;
Schlaepfer et al., 1994). FAK interactions with integrins and growth
factor receptors contribute to cell anchorage dependency, motility,
and invasive growth, which are associated with malignant overgrowth
and pro-survival.
Human FAK, encoded by the protein tyrosine kinase 2 gene, consists
of N-terminal FERM, central catalytic, and c-terminal focal adhesion
targeting (FAT) domains. The N- and C-terminal domains of FAK form
an autoinhibitory structure (Lietha et al., 2007). FAK interactions with
membrane receptors including integrins and IGF1R are believed to in-
duce a conformational switch of FAK to expose phosphorylation sites
such as Y397. Phosphorylation of FAK at Y397 can promote FAK binding
and phosphorylation of acceptor proteins including Src. FAK activation
of Src can stimulate several signal transduction pathways such as
PI3K-Akt, RAF/JNK, and Rho/Rac/PAK (J. Zhang et al., 2013). Activation
of those cascades modulates cell motility and survival. For example,
Y397 phosphorylation of FAK plays a critical role in cell migration (Ritt
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Fig. 1. FAK modulation of cancer cell glucose consumption and proliferation. Growth fac-
tors, insulin/IGF1R, and/or anchorage-activated integrin trigger FAK activation. Down-
stream factors, IRS and PI3K/Akt induce alteration of glycolysis and mitochondrial
respiration. Excessive glucose consumption provides energy and precursors to rapidly
growing cells. Inhibitors targeting FAK or FAK-IGF1R interactions can prevent malignant
cell glucose consumption and growth.
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removal of autoinhibition and release of the FAT domain (Gervais
et al., 1998). The FAT fragment inhibits FAK activity through dephos-
phorylation and induces cell death.
Overexpression and hyperphosphorylation of FAK are associatedwith
many types of solid tumors. Lethality of FAKknock out indicates an essen-
tial role of FAK in fetal development. In adult tissues, FAK levels are rela-
tively low, but can be elevated duringwound healing and transformation
processes (Gates et al., 1994; Moissoglu & Gelman, 2003; Tamura et al.,
2003; Nagaharu et al., 2011). Hyperactivity of FAK can promote survival
andmotility, contributing to tumorigenicity andmetastasis. For example,
the levels of FAK expression were low in the normal colon or benign
breast epithelium but high in the biopsies derived from patients with
colon and metastatic breast cancer (Cance et al., 2000; Lark et al., 2005).
Furthermore, the levels of FAK mRNA in normal tissues were very low,
but were overexpressed in varied primary and metastatic tumors
(Golubovskaya et al., 2009). FAK overexpression and phosphorylation
were associated with Barrett's associated esophageal adenocarcinoma,
prostate-carcinoma, gastric cancer recurrence, squamous cell carcinoma,
progression of hepatocellular carcinoma, thyroid cancer, small-cell lung
carcinoma, and oral tumor cell invasion (Aprikian et al., 1997; Rovin
et al., 2002; Schneider et al., 2002; Aronsohn et al., 2003; Itoh et al.,
2004; Kim et al., 2004; Watanabe et al., 2008; Lai et al., 2010; Yuan
et al., 2010; Ocak et al., 2012).
The mitogenic effects of FAK on cell proliferation and survival in nor-
mal and neoplastic tissues have been well accepted and reviewed
(Zachary & Rozengurt, 1992; Schlaepfer et al., 1994; Hauck et al., 2002;
Lietha et al., 2007; G. Liu et al., 2008; Ucar & Hochwald, 2010). The role
of FAK inmetabolismunder normal anddisease conditions such as cancer
has not been critically evaluated or summarized. Increasing evidence in-
dicates a role for FAK modulation of glucose, lipid and glutamine metab-
olism that is likely essential for tumor cell rapid growth, survival and
invasion.
2. FAK-promoted glucose consumption in neoplastic proliferation
Growth factors such as insulin/IGF-1 and anchorage are primary ex-
tracellular cues that stimulate cell proliferation. FAK interactions with
IGF-1R and integrins transmit these growth signals by activating effec-
tors such as PI3K/Akt, promoting glucose consumption to fuel rapid
growth in tumor cells (Fig. 1).
2.1. FAK modulation of insulin-stimulated glucose uptake
The direct binding of FAK with insulin receptor substrate (IRS)
proteins and the role of FAK in controlling expression of insulin receptor
substrate-1 (IRS-1) has been previously shown (Lebrun et al., 2000).
Insulin binds to its receptors, triggering IRS-FAK activation and intracellu-
lar signal cascades that mediate a number of cellular processes including
an increase in glucose transport (Knight et al., 1995; Pillay et al., 1995;
Ouwens et al., 1996; Baron et al., 1998; Lebrun et al., 2000; El Annabi
et al., 2001; Goel & Dey, 2002; Huang et al., 2002). FAK activation reorga-
nizes actin ﬁlaments to form a mesh harboring the glucose transporter.
Translocation and activation of transporter 4 promotes glucose uptake
through PI3K/Akt activation in skeletal muscle cells (Bisht & Dey, 2008).
Furthermore,ﬁbronectin activation of FAK through integrin-ECM interac-
tion stimulates glucose uptake in endothelial cells (Paik et al., 2009). In
hepatocytes, FAK modulates glycogen synthesis by stimulating Akt/
GSK-3β signaling (Huang et al., 2002).
Oncogenes alter metabolic pathways, contributing to increased glu-
cose uptake and dependency for cancer cell viability. This unique fea-
ture of malignant cells has been applied to tumor detection using
positron emission tomography imaging with the radiolabeled glucose
analog 18F-ﬂuorodeoxyglucose. High levels of glucose increase
integrin-ECM stimulation of FAK activity and enhances stem cell prolif-
eration (Kroder et al., 1996). On the other hand, glucose withdrawalinduces aberrant tyrosine phosphorylation of focal adhesion protein in
glucose-dependent cell lines such as glioblastoma, sarcoma, and mela-
noma (Grahamet al., 2012). FAKmodulation of insulin signaling is likely
to be cell type speciﬁc since FAK activation is negatively correlatedwith
glucose uptake in neuronal cells (Gupta et al., 2012).
Glucose is one of the major cellular sources of energy and building
materials that are required for proliferation. FAK stimulation of glucose
uptake is expected to be correlatedwith increased proliferation. Indeed,
FAK overexpression or hyperactivation is common in solid tumors. In
addition, tyrosine kinases including FAK modulate the levels of glucose
transporters (Anichini et al., 1997; Bisht & Dey, 2008) and the prolifer-
ation index (Zhelev et al., 2004; Liu et al., 2007; Serrels et al., 2012) in
muscle and tumor cells.
2.2. FAK-IGF1R signaling in tumor glucose metabolism
IGF-1/IGF1R signaling has potent effects on cell survival through pro-
moting proliferation and suppressing apoptosis. The metabolic effects of
the IGF-1/IGF1R axis on glucose metabolism are less known. Several
lines of observations support the role of the IGF-1/IGF1R cascades in
glucose processing. First, IGF1R often forms complexes with insulin re-
ceptors. Thus, IGF1R can have inﬂuence on insulin stimulation of glucose
consumption via the insulin receptor/IGF1R complex. Secondly, IGF-1 can
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Fig. 2. The roles of FAK in lipid-mediated tumor growth and invasion. FAK interactions
with receptors such as IR/IGF1R/integrin and effectors such as PI3K/Akt/ERK are associated
with lipid rafts. Formation and translocation of FAK-associated lipid complexes contrib-
utes to ACLY and FASN activation, channeling TCA-processed glucose to promote lipogen-
esis. Excessive lipid biosynthesis can induce cell growth and lipid turnover-mediated
motility. Inhibition of ACLY and FASN leads to decreased lipid biosynthesis and tumor
growth/invasion.
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tion of glucosemetabolism. Thirdly, IGF-1/IGF1R stimulation of rapid pro-
liferation needs sustained energy and cellular biosynthesis. IGF1R
stimulated glucose uptake can meet this high demand (Kuemmerle,
2012).
Activation of IGF-1R signaling is correlated with primary and meta-
static malignancies such as prostate, breast, pancreatic, and lung cancer
(Resnik et al., 1998; Putz et al., 1999; Warshamana-Greene et al., 2005;
Moser et al., 2008). The anti-apoptosis property of IGF1R-triggered
kinase cascades contributes to cancer cell resistance to cytotoxicity
and vascularization. When EGFR pathways are blocked by inhibitors
such as Erlotinib, IGF1R can resume EGFR-related signaling and
promote breast cancer survival. IGF1R-enhanced angiogenesis is
involved in tumor invasion and metastasis (Kucab & Dunn, 2003;
Menu et al., 2007; Ackermann et al., 2012).
The Hochwald laboratory and others have demonstrated FAK inter-
action with and stabilization of IGF1R (W. Liu et al., 2008; Andersson
et al., 2009). The N-terminal FERM domain of FAK directly binds to
IGF1R, leading to PI3K/Akt activation and survival. Small molecule inhi-
bition of FAK-IGF1R interactions induces apoptosis and prevents tumor
growth. Antibody-mediated inhibition of IGF1R signaling results in
decreased Akt activity and glucose uptake (Shang et al., 2008). Impaired
kinase-independent biological functions of IGF1R leads to decreased
intracellular glucose levels and viability of cells derived from human
embryonic kidney and metastatic breast cancer (Janku et al., 2013).
2.3. Clinical associations of increased glucose levels and cancer risk
Increased glucose uptake and associated metabolism are hallmarks
of malignancy. Abnormal IGF1R signaling can contribute to tumor met-
abolic pathways since increased IGF1R mass and/or activity may en-
hance insulin receptor-induced glucose utilization. IGF1R signaling
may promote the shift of cellular balance favoring biosynthesis to sup-
port neoplastic proliferation. Several studies show that high glucose
levels are correlated with increased cancer risk (Kabat et al., 2012;
Chocarro-Calvo et al., 2013; Wulaningsih et al., 2013). A large clinical
study (540,309 participants) demonstrated that high serum glucose
levels were linked with increased risks of development of colon cancer
(Wulaningsih et al., 2012). Quartile analysis indicated a positive associ-
ation between glucose levels and risks of kidney cancer (VanHemelrijck
et al., 2012). These observations demonstrate the possible need for
monitoring aberrant glucose levels or metabolism to identify individ-
uals at high risk of developing certain types of malignancies such as
colon cancer (Aleksandrova et al., 2011).
3. Lipid-FAK interactions in tumorigenesis
3.1. The role of lipids in FAK-promoted tumor motility and invasive growth
Lipid metabolism can affect the scaffolding and kinase functions of
FAK (Fig. 2). Lipids in the cell membrane provide the necessary microen-
vironment for FAK interactions with receptors such as integrins and
IGF1R. In addition, lipid rafts can facilitate the translocation of FAK-
associated complexes in FAK-promoted signal transduction. For example,
lipid rafts are associated with FAK stimulation of ERK1/2 and neurite
outgrowth (Niethammer et al., 2002). Lipid rafts and FAK interactions
contribute to cell adhesion signaling (Shima et al., 2003).
FAK activation and association with Src family members can transmit
growth cues by forming complexes with membrane-bound receptors
such as integrins, IGF1R, and EGFR in lipid rafts. Indeed, translocation of
the neuronal cell adhesion molecule from FGFR complexes into FAK-
associated lipid rafts promotes focal adhesion assembly, cell motility
and invasive growth (Lehembre et al., 2008). Disrupting the lipid rafts
attenuates EMT and cell spreading (Lehembre et al., 2008). A synthetic
lipid analog promotes the invasiveness of colon cancer cells throughupregulation of integrin-FAK phosphorylation/activation, interactions,
and scaffolds (Van Slambrouck et al., 2007).
3.2. FAK and lipid metabolism in neoplastic growth
FAK can affect lipid metabolism by controlling the supply of precur-
sors and enzyme activity of proteins involved in lipid synthesis. Citrate
is exported from mitochondria into the cytosol and converted to fatty
acid (Fig. 2). Growth factor and anchorage-dependent activation of
FAK enhances glucose uptake. This can maintain the carbon supply for
increased lipid synthesis in proliferative cells.
FAK and fatty acid biosynthesis: Citrate conversion to acetyl-CoA,
malonyl-CoA, long chain fatty acid, and unsaturated fatty acid oleate
involves ACLY, acetyl-CoA carboxylase, fatty acid synthetase, and
stearoyl-CoA desaturase (Fig. 2). Aberrant enzyme activity and de
novo lipogenesis are associated with many types of solid tumors such
as lung, gastric, and breast cancers (Varis et al., 2002; Yancy et al.,
2007; Migita et al., 2008). SREBP-1 activation of PI3K/Akt signaling
and Myc-regulated glutaminolysis to lipid metabolism are linked to
metabolic reprogramming in cancer cells (Guo et al., in press). Inhibi-
tion of key lipogenic enzymes, ACLY and fatty acid synthetase, decreases
FAK, Akt, and paxillin activity and cell motility (Zaytseva et al., 2012).
Insulin activation of ACLY involves FAK-induced phosphorylation/
translocation of insulin receptors (Brownsey et al., 1984). Depletion of
raft cholesterol impairs chemokine and growth factor stimulated FAK
recruitment and adhesion, thus, contributing to anoikis like apoptosis
(Le et al., 2005; Ramprasad et al., 2007; Park et al., 2009; Jeon et al.,
2010).
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Fig. 3. FAK activation and cancer dependency on glutamine. FAK activation of oncogenes,
K-Ras and Myc, alters the activities of glutamine synthetase and glutaminase. Increased
glutamine ﬂuxprovides precursors for nucleic acid andprotein synthesis that are essential
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Cancer and proliferating cells have enhanced the biosynthesis of
fatty acids by channeling glucose and/or glutamine into the TCA cycle
and upregulation of lipid biosynthetic enzymes (Ridgway, 2013). The
levels of certain lipid components and lipogenic enzymes are associated
with the risks of kidney and breast cancer (Van Hemelrijck et al., 2012;
Wang et al., 2013). High fat diets stimulate bile acid secretion into the
gastrointestinal tract. Bile acids are correlated with colon cancer,
and lipid-lowering drugs may reduce the risk of colorectal tumor
(McMichael & Potter, 1985; van Duijnhoven et al., 2011; Cai et al.,
2012; Simon et al., 2012). At high physiological levels, the bile acid
deoxycholic acid, induced colonic tumor formation in mice (Bernstein
et al., 2011). Deoxycholic acids decreased phosphorylation of FAK at
tyrosine-576/577 (Tyr-576/577) and Tyr-925, promoted Src binding
with FAK, and triggered inside-out signaling in colon cancer cells
(Khare et al., 2006). FAK interactions with Src can induce downstream
cascades including PI3K/Akt. Indeed, bile acid-induced colon cancer
is likely associated with PI3K/Akt signaling-increased survival and
proliferation (Raufman et al., 2008).
4. FAK-associated deregulation of glutamine
metabolism in cancer cell survival and proliferation
Many cancer cells such as pancreatic ductal adenocarcinoma rely on
glutamine for their survival and biosynthetic needs (Wilson et al.,
2013). Although the direct link of FAK activation and glutamine
deregulation warrants further investigation, current data suggests that
the scaffold and kinase functions of FAK can contribute to cell sensing
microenvironmental cues and modulation of amino acid and protein
metabolism. For example, FAK activation is associated with K-Ras and
H-Ras induced transformation of NIH3T3 cells and rat ﬁbroblasts (Jeon
et al., 2007). In addition, aberrant activation of oncogenes such as Myc
and K-Ras mediate reprograming of glutamine metabolism (Wise &
Thompson, 2010; Son et al., 2013) (Fig. 3). FAK hyper-activation is
associated with uncontrolled cancer survival and proliferation.
Targeting malignancy-speciﬁc glutamine consumption provides a
unique approach to attack solid tumors.
4.1. FAK and glutamine dependency for tumor growth and invasion
Proliferating cells consume glutamine to fuel the tricarboxylic acid
cycle and provide nitrogen for nucleotide, nonessential amino acid and
hexosamine biosynthesis (Fig. 3). Cancer cells often develop dependency
on speciﬁc amino acids (Fu et al., 2003). For example, deprivation of tyro-
sine and phenylalanine in the medium induces apoptosis of melanoma
cells through FAK-related signaling pathways (Fu et al., 1999). Glutamine
metabolism is dramatically increased in Her2-type breast cancer (Kim
et al., 2013). Oncogene K-Ras modulation of glutamine metabolism is es-
sential for pancreatic cancer cell survival and growth (Son et al., 2013).
FAK interactions with Her2 promote tumorigenesis (Vartanian et al.,
2000; Lark et al., 2005). Furthermore, micrometastatic cells express
activated/phosphorylated FAK, Her2 and PI3K, suggesting the roles
of Her2-FAK/Src-PI3K activation in malignant and invasive growth
(Vadlamudi et al., 2003; Kallergi et al., 2007).
4.2. The association of FAK activation and
glutamine-modulated autophagy in cancer cell survival
Autophagy is a key strategy for cell survival under stress conditions
such as nutrient deﬁciency. Degradation of non-essential and/or redun-
dant cellular compartments leads to release of building blocks to fuel
key energy and biosynthetic processes. Cancer cells can capture this
machinery to retain their pro-survival and proliferative states. For in-
stance, pancreatic cancer cells have elevated levels of autophagy, and
suppression of autophagy prevents proliferation and tumor growth.FAK stimulates PI3K/Akt signaling;whereas PI3K/Akt activation increases
the levels of glutamine and its synthetase (van der Vos et al., 2012).
Increased glutamine production promotes autophagy, survival and prolif-
eration (Nicklin et al., 2009; Sakiyamaet al., 2009;Ko et al., 2011; Liu et al.,
2013). These observations support the notion that growth factor stimula-
tion of FAK-PI3K-Akt signaling contributes to cell survival and prolifera-
tion through upregulation of glutamine synthetase and autophagy.4.3. FAK modulation of glutamine
metabolism in stress-resistant neoplastic cells
Rapid cell proliferation demands energy and building blocks.
High levels of energy generation and biosynthesis are correlated
with production of byproducts such as oxidants. In order to cope
with excessive oxidants, FAK-overexpressing solid tumors must up-
regulate signaling pathways that promote antioxidant production.
Growth factor-FAK-PI3K/Akt signaling resulting in increased gluta-
mine synthetase and glutamine levels can serve as anti-oxidative
machinery. Son et al., observed that glutamine deprivation suppresses
pancreatic ductal tumor cell growth through a non-canonical pathway
of glutamine consumption that is involved in serial conversion of
glutamine-oxaloacetate-malate-pyruvate (Son et al., 2013). This process
leads to increased NADPH/NADP+ ratios, which has anti-oxidative
activity. Antioxidants, GSH and N-acetylcysteine, abolish glutamine
deﬁciency-suppressed cancer cell growth (Son et al., 2013), suggesting
that cancer cells use glutamine metabolism to maintain cellular redox
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oxidative stress in intestinal epithelial cells (Musch et al., 1998).
Glutamine supplements attenuate 2,4,6-trinitrobenzene sulfonic acid-
induced oxidative stress in a rat model of colitis (Crespo et al., 2012).
Increased ﬂux of glutamine toward glutathione synthesis reduces oxida-
tive stress in ﬂies and human cell lines (Nicolay et al., 2013). A direct link
of FAK modulation of glutamine metabolism in neoplastic cells has not
been shown at this time.
4.4. The link between aberrant glutamine metabolism and tumorigenesis
Excessive glutamine consumption contributes tomalignant survival,
genomic instability, and unscheduled proliferation (Fernandez-Marcos
& Serrano, 2013; Jeong et al., 2013). Use of small molecules targeting
glutamine metabolism allows linkage of the Rho GTPases and NF-κB
to mitochondrial glutaminase hyper-activity in cancer cells (Wilson
et al., 2013). Abnormalities in glutamine metabolism has been linked
to pancreatic, lung, and breast cancer, which are associated with onco-
genes such as K-Ras, solute-linked carrier family A1member 5 andMyc
(Dang, 2013; Hassanein et al., 2013; Kim et al., 2013; Son et al., 2013).
The role of FAK in glutamine deregulation-associated tumorigen-
esis include: 1) activating glutamine metabolism-related oncogenes
such as K-Ras, 2) relaying signals from oncogenes to glutamine met-
abolic enzymes, and 3) direct regulation of glutamine metabolism.
FAK levels are often elevated in solid tumors. siRNA inhibition of
FAK expression attenuates EGF and ﬁbronectin-stimulated overex-
pression of oncogenes and cell cycle regulatory proteins, resulting
in decreased cell migration and proliferation (Park & Han, 2009;
Park et al., 2011). Phosphorylation of FAK at tyrosine 407 negatively
regulates FAK activity. Decreased Y407 phosphorylation is correlated
with Ras transformation of ﬁbroblasts, indicating that FAK activation
stimulates Ras signaling (Jeon et al., 2007; Wade et al., 2011). On the
other hand, R-Ras promotes FAK signaling, and synergizes with
alpha2beta1 integrin stimulation of FAK activation (Kwong et al., 2003).
Furthermore, Myc activates FAK in neuroblastoma cells (Beierle et al.,
2007). Glutamine restriction inhibits FAK activity and impairs melanoma
attachment and spreading, suggesting the involvement of FAK in
glutaminemetabolism-modulatedmalignant cell anchorage andmotility
(Fu et al., 2004).
5. Targeting FAK-mediated metabolic signaling pathways
The interplay among glycolytic/mitochondrial glucose processes,
lipid biosynthesis, and nucleotide/protein/antioxidant metabolism are
dynamically balanced in response to a constantly changing microenvi-
ronment. FAK overexpression and hyperactivation can promote glucose
metabolism to fuel cell proliferation in cancer cells (Fig. 4). Targeting
FAK activation and its interactions with proteins that are involved in
glucose, fatty acid, and glutamine metabolism can be an attractive
approach to combat tumor growth and metastasis. Inhibitors targeting
FAK function, FAK binding with IGF1R, FAK-activated key lipogenic
enzymes and glutamine synthetase have been developed (Vander
Heiden, 2011). The NIH clinical trial database (clinicalTrial.gov) and
PubMed have been searched to identify inhibitors targeting FAK activity
and its metabolic pathways.
5.1. FAK inhibitors
VS-6063 and VS-4718 are drug candidates, developed by Verastem,
for FAK inhibition targeting cancer stem cells. A phase I/Ib clinical trial
has been conducted with Paclitaxel in combination with the company's
ﬁrst FAK inhibitor, defactinib or VS-6063, in subjects with advanced
ovarian cancer. Verastem reports that VS-6063 was granted orphan
drug status by the US FDA and European regulators for mesothelioma,
an asbestos-related rare lung cancer with limited treatment options.
Verastem also reports that VS-6063 was well tolerated at the dose of400 mg BID in combination with weekly Paclitaxel. Previously, pre-
clinical studies indicated that VS-6063 (formerly PF-04554878) reduced
cancer stem cells, primary tumor mass and metastasis (Schultze &
Fiedler, 2011). A recently completed Phase I clinical study shows that
the FAK inhibitor, PF-00562271, is tolerated at a dose of 125 mg BID in
patients with pancreatic, head and neck, prostatic neoplasms (Infante
et al., 2012).
VS-4718 is the second compound, developed by Verastem, currently
under study in a phase I clinical trial evaluating patients withmetastatic
non-hematologic malignancies.
GSK2256098 is a small molecule inhibitor of FAK developed by
GlaxoSmithKline. A phase I clinical trial dose escalation study in subjects
with solid tumors known to express FAK has been performed. Prelimi-
nary ﬁndings from the ﬁrst trial of GSK2256098 in subjects with meso-
thelioma suggested that it had some effects on disease spread in
patients lacking an active tumor suppressor gene, NF2 ((ECCO), 2012).
Numerous new FAK inhibitors have been designed, produced, and
tested, including diarylamino-1,3,5-triazine, 1,3,4-oxadiazole, pyrazolo
[4,3-c][2,1]benzothiazines derivatives, cFAK-C4 and Y15 (Dunn et al.,
2010; Schultze & Fiedler, 2010; Ma, 2011; Dao et al., 2013; S. Zhang
et al., 2013; Tomita et al., 2013).
5.2. Inhibitors targeting FAK activation of IR/IGF1R
Insulin and IGF-1 can stimulate FAK activity (Baron et al., 1998); and
FAK binds with and stabilizes IGF-1R. Therefore, FAK hyperactivity can
promote insulin/IGF-1 signaling-mediated glucose metabolism in can-
cer cells. Blocking basic insulin signaling can cause serious metabolic
disorders. Inhibitors targeting IGF1R have been developed in the at-
tempt to attenuate tumor growth.
IGF1R inhibitors: Several companies are currently testing small mol-
ecule kinase inhibitors targeting the IGF1R tyrosine kinase and many
have had limited utility (Pollak, 2008; Hewish et al., 2009). Over 50 clin-
ical trials of IGF1R inhibitors in patientswithmany types of tumors have
been registered with NIH (Clinicaltrials.gov, August 2013). Inhibitor
names, tumor types, trial stages and statuses are summarized in
Table 1. Approaches targeting the ATP competitive binding site have
limitations due to lack of speciﬁcity for IGF1R. This is due to sequence
homology and identity, particularly in the kinase domain, and structural
similarity of IGF1R to other receptor tyrosine kinases such as the insulin
receptor. A similar argument can bemade for kinase inhibitors of FAK. In
addition, it appears that disruption of the kinase domain is not sufﬁcient
to speciﬁcally interfere with the downstream signaling of IGF1R (or
FAK) and it is unclear whether the kinase function or the scaffolding
function of these proteins is more important (Golubovskaya et al.,
2012; Su et al., 2013).
Targeting FAK-IGF1R interaction represents a novel approach to in-
hibit abnormal hyperactivation of survival signaling. Both FAK and
IGF-1R are upregulated and promote the malignant phenotype making
them appropriate targets for developmental therapeutics. We have
shown that dual inhibition of FAK and IGF1R leads to a synergistic
increase in cell detachment and apoptosis (W. Liu et al., 2008;
Hochwald et al., 2009; Zheng et al., 2010). However, selective dual
small molecule inhibitors of both proteins are not available or demon-
strate toxicity (Golubovskaya et al., 2008; Watanabe et al., 2008;
Kurenova et al., 2009). Inhibitors targeting FAK protein binding with
IGF1R offer signiﬁcant promise to inhibit the function of both FAK and
IGF-1R proteins and be more efﬁcacious than existing IGF-1R inhibitors
that have failed testing in clinical trials. These FAK inhibitors may be as-
sociated with low rates of side effects for the following reasons: 1) FAK-
IGF1R signaling can primarily stimulate abnormal survival signaling.
Speciﬁc inhibition of FAK FERM domain binding with IGF1R should
have minimal effects on FAK binding with other partners, indicating a
limited impact on basic signaling. 2) FAK levels decrease after fetal
development to very low levels in adult normal tissues; therefore,
these inhibitors can have less impact on normal tissues.
FAK Modulation of Cancer Cell Metabolism
Tumor Growth
PI3K/Akt
Glycolysis
FAK
IRS
Excessive Glucose Consumption
Lipid, Nuclei acid and protein synthesis
Insulin/IGF-1
IR/IGF1R
TCA
Citrate Acetyl-CoA LipidBiosynthesis
FAK
Integrin
Glutamate Glutamine
Nuclei/Protein
Biosynthesis
Antioxidants
K-Ras/Myc
ERK1/2
Akt
Glucose
GLUT
Fibronectin
Fig. 4. FAK modulation of cancer cell metabolism. Insulin/IGF1 stimulates FAK-PI3K-Akt signaling through IRS. This modulates glucose metabolism via activation of glucose transporters,
glycolytic andmitochondrial enzymes. Citrate can leave the TCA cycle inmitochondria and is converted to lipids. FAK activation of ERK/Akt can promote this conversion and channel glu-
cose to lipids for the biosynthetic needs of rapidly growing cells. Anchorage-dependent stimulation of FAK activity contributes to K-Ras/Myc signaling-related glutamine metabolism.
159J. Zhang, S.N. Hochwald / Pharmacology & Therapeutics 142 (2014) 154–163Small organicmolecules are particularly attractive as inhibitors of in-
tracellular protein–protein interactions because of the ability to modify
their structures to achieve optimal target binding, and because of their
ease of delivery in in vivo systems. Several investigators have developed
an approach for therapeutic intervention by targeting FAK-IGF1R
protein-protein binding. Molecular docking, cell-based screening and
xenograft mouse models have been used for the identiﬁcation of lead
compounds such as INT2-31 that inhibit FAK-IGF1R binding and
tumor growth (Ucar et al., 2012, 2013).
5.3. Targeting ACLY and fatty acid synthetase
ACLY hyperactivation is a common feature of many tumors and is
correlated with FAK overexpression. Inhibition of ACLY activity inducesthe arrest of cancer cell cycle progression in vitro and in vivo (Zaidi et al.,
2012;Migita et al., 2013). ACLY deﬁciency exerts an anticancer effect via
increased ROS and p-AMPK (Migita et al., 2013). These observations
support the notion that FAK-ACLY signaling contributes to increased li-
pogenesis in cancer cells, but potent and speciﬁc antagonists to inhibit
abnormal constitutive activation of these proteins are lacking.
Normal cells rely on dietary fatty acids. Therefore, depletion of fatty
acid synthetase has limited impact on normal cells. FAK and fatty acid
synthetase are often highly upregulated in solid tumors. Furthermore,
fatty acid synthetase is essential for cancer cell survival. Inhibition of
fatty acid synthetase induces apoptosis. Inhibitors targeting fatty acid
synthetase prevent the cell proliferation and growth of prostate cancer
(Chen et al., 2012). Several potent inhibitors of fatty acid synthetase
have been patented and are commercially available (Pandey et al.,
Table 1
Clinical trials of IGF1R inhibitors in subjects with cancer.
The NIH ClinicalTrials.gov database has been searched to identify studies on inhibitors
targeting IGF1R signaling in solid tumors. Inhibitor names, tumor types, trial stages and
their status/conclusions are summarized (clinicalTrial.gov) (Lacy et al., 2008; Molife
et al., 2010; Scagliotti & Novello, 2012).
Name Tumor Trial phase/
NIH number
Status/
conclusion
PL225B Advanced refractory solid
tumors
Phase 1/
NCT01779336
Recruiting
OSI-906 Breast cancer Phase 2/
NCT01013506
Withdrawn/
toxicities
and
progressed
Multiple myeloma Pahse 1 & 2/
NCT01672736
Recruiting
Lung cancer Phase 2/
NCT01387386
Recruiting
AXL1717 Non-small-cell lung cancer Phase 1/
NCT01466647
Completed/
No results
posted
Glioblastoma, gliosarcoma
Anaplastic astrocytoma
Anaplastic oligodendroglioma
Anaplastic oligoastrocytoma
Anaplastic ependymoma
Phases 1 & 2/
NCT01721577
Recruiting
Non-small-cell lung cancer
Squamous cell carcinoma
Adenocarcinoma of the lung
Phase 2/
NCT01561456
Recruiting
Solid tumors
Hematological malignancies
Phase 1/
NCT01062620
Completed/
no results
posted
CP-751,871 Carcinoma, squamous Cell;
Carcinoma, adenosquamous;
Carcinoma, large cell;
Carcinoma, non-small-cell
lung
Phase 3/
NCT00673049
Terminated/
progressed
Multiple myeloma Phase 1/
NCT01536145
Completed/
tolerated
Solid tumors Phase 1/
NCT00474760
Completed/
tolerated
RAD001 + AMG479 Neoplasm metastases Phase 1/
NCT01122199
Recruiting
AVE1642 Liver carcinoma Phases 1 & 2/
NCT00791544
Withdrawn/
discontinued
MK-0646 Non-small-cell lung cancer Phase 2/
NCT00799240
On-going
Pancreatic cancer Phases 1 & 2/
NCT00769483
Recruiting
R1507 Neoplasms Phase 1/
NCT00400361
Completed/
tolerated
XL228 Cancer, lymphoma Phase 1/
NCT00526838
Terminated/
discontinued
160 J. Zhang, S.N. Hochwald / Pharmacology & Therapeutics 142 (2014) 154–1632012). Since the levels of FAK and fatty acid synthetase in normal tissues
are low or undetectable, clinical trials of fatty acid synthetase inhibitors
in patientswith tumors overexpressing FAK and/or fatty acid synthetase
may result in the discovery of potent anti-cancer drugs with minimal
side-effects. No trials evaluating fatty acid synthetase inhibitors in ma-
lignancy have been reported to date.
5.4. Inhibition of aberrant glutamine metabolism
FAK can enhance the activities of oncogenes such as K-Ras and
Myc; while their activation has been linked to increased glutamine
synthetase activity. Derivatives of methionine sulfoximine, phos-
phorus containing analogues of glutamic acid, bisphosphonates and
miscellaneous inhibitors targeting glutamine synthetase have been
developed (Berlicki, 2008). A glutaminolytic drug, L-Asparaginase,
and the glutamine synthetase inhibitor, methionine sulfoximine, de-
pleted the glutamine pool, arrested cell cycle progression, and in-
duced caspase-3 mediated apoptosis in human hepatocellular
carcinoma cells (Tardito et al., 2011). Oncogenic Myc promotes glu-
taminase expression and cancer cell addiction to glutamine (Wiseet al., 2008). Inhibition of glutaminase activity using siRNA or small
molecule, BPTES [bis-2-(5 phenylacetamido-1, 2, 4-thiadiazol-2-yl)
ethyl sulﬁde], prevented growth and tumorigenesis (Lobo et al., 2000;
Thangavelu et al., 2012). Glutaminase inhibitors attenuate cancer-
related gene expression through histone and epigenome modiﬁcation
(Simpson et al., 2012). A cell-permeable benzophenanthridinone
compound 968 inhibits mitochondria glutaminase, resulting in re-
pressed growth and invasive activity in NIH3T3 cells expressing
Dbl, Cdc42-F28L, Rac-F28L or RhoC-F30L mutants, in SKBR3 and in
MDA-MB231 cancer cells. The observations suggest that the balance
of glutamine and glutamate plays a vital role in tumor cell survival.
Depletion of either glutamine or glutamate pools in the tumor cells
can lead to oxidant production and apoptosis. Although preclinical
results have shown the anti-cancer effects of targeting glutamine
metabolisms, there is no clinical trial that is registered in the NIH
clinical trial data base as of August, 2013.
6. Summary and prospective
FAK plays a key role in tumor metabolism that is characterized by
excessive consumption of and addictive dependency on glucose, lipids
and glutamine. Constitutive FAK binding with and stabilization of IR/
IGF1R promotes effectors such as IRS and PI3K/Akt cascades, promoting
glucose consumption to fuel rapid cell division and enhance survival.
Lipids aremajor components of cellmembranes that are essential for
excessive cell proliferation. The role of FAK in tumor lipidmetabolism is
less well studied. However, experimental evidence supports the notion
that FAK can contribute to the malignant cell deregulation of lipid
bioprocesses. First, FAK interactions with membrane receptors such as
integrins, EGFR, and IGF1R to form complexes are critical for initiation
of lipid biosynthesis. Second, FAK activation is correlated with overex-
pression of lipid enzymes. Finally, FAK-promoted glucose consumption
can provide carbon sources for lipid synthesis.
Oncogene-induced glutamine consumption can fuel rapid cell
growth andmaintain redox balance in cancer cells. Constitutive FAK ac-
tivation stimulates oncogenes such as K-Ras and Myc, which promotes
the activities of glutaminemetabolic enzymes including glutamine syn-
thetase and glutaminase. Increased levels of cellular glutamine pools
boost TCA-mediated metabolic pathways and antioxidant production,
which is essential for rapid cell proliferation.
Deﬁning and establishing the link between FAK-related pathways
and abnormal metabolism can promote the design and development
of new drugs for the treatment of cancer. For example, inhibitors
targeting FAK modulation of IGF1R, ACLY, and glutaminase have been
reported to attenuate abnormal glucose, fatty acid and glutamine con-
sumption as well as tumorigenesis. However, clinical trials of those po-
tent inhibitors in patientswith tumors are lacking. It is expected that the
development of new potent small molecules and further clinical studies
of the known inhibitors targeting FAK and/or its downstreammetabolic
effectors can lead to the identiﬁcation of novel compounds to kill cancer
cells with minimal side-effects on normal tissues.
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